Delisting risk
RedHill Biopharma (ADR)
Specialty biopharmaceutical developer behind Talicia and a partner-led oral-medicine pipeline.
$0.7990
Pre-market−0.11 (−12.38%)
At close$0.9119(+37.96%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
3.14M ADS as of Aug 22, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Alumni Capital LP | 9.99% | 369.4K | 13G | Oct 20, 2025 ↗ |
| YA II PN, Ltd. | 9.90% | 508.7K | 13G | Dec 23, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 10, 2026 | Gilead Radayofficer: Chief Operating Officer | Sale | 14,130,000 | $0.0001 | 218,780,000 |
| Apr 6, 2026 | Gilead Radayofficer: Chief Operating Officer | Sale | 15,740,000 | $0.0001 | 261,060,000 |
CongressHouse and Senate disclosures
Not reported.